// App-Quantinova.ai

1403 : Outcomes following first-line immunotherapy with or without chemotherapy stratified by KRAS mutational status – A real world analysis in patients with advanced NSCLC

Researchers

Presenter

  • Charu Aggarwal

Principal Investigators

  • Halla Nimeiri

  • James Chen

  • Iker Huerga

  • Leora Horn

  • Nataliya Trunova

  • Jyoti Patel

Medical Centers

  • University of Pennsylvania, Philadelphia, PA

  • AstraZeneca, Chicago, IL, USA

  • Robert H. Lurie Comprehensive Cancer Center, Chicago, IL

  • Tempus, Chicago, IL

  • Northwestern University, Chicago, IL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • KRAS proto-oncogene, GTPase

  • Programmed death-ligand 1

  • Liver kinase B1

  • Kelch Like ECH Associated Protein 1

  • Tissue polypeptide-specific antigen

  • Tumor protein p53

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved